Park Square Executive Search has placed Pete Ligotti as Chief Commercial Officer at Elutia, a pioneer in drug-eluting biomatrix technologies. Ligotti will lead the commercialization of NXT-41x, Elutia’s next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. Built on the company’s validated drug-eluting platform, NXT-41x addresses a significant unmet need in breast reconstruction, where infection rates remain high despite widespread adoption of biologic mesh in a $1.5B U.S. market. As Elutia prepares for anticipated FDA clearance in 2027, the company is positioning itself to deliver a new standard of care in a large and underserved market.

Ligotti brings twenty years of commercial execution in complex surgical markets, including having built Integra LifeSciences' plastic and reconstructive surgery commercial operation from the ground up, before expanding into broader leadership roles spanning neurosurgery, orthopedics, and specialty surgery. In Europe, he scaled Integra’s specialty surgical business to over $180 million in revenue in four years and later led the extremity orthopedics division through a $240 million divestiture to Smith & Nephew. Previously, at NuVasive, he led a complex business turnaround, delivering 40% revenue growth before the division was acquired by Globus Medical.

Ligotti holds a B.Sc. in Biology from Syracuse University.